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Prevention of stroke is, of course, the ideal scenario, 
but with more than 10 million major strokes every year 
worldwide, acute treatment and rehabilitation should 
also be optimised. Organised acute stroke care within 
dedicated stroke units reduces death and dependency 
after stroke,1 but which elements of such care confer this 
beneﬁ t is uncertain. Systematic prevention of common 
complications and more expert nursing care undoubtedly 
contribute, but in the physiologically unstable setting 
of acute stroke, the beneﬁ ts and harms of each speciﬁ c 
element of care need to be reliably assessed.
How soon and how intensively patients with acute 
stroke should be mobilised is an obviously important 
question. Early mobilisation after stroke, whether sitting, 
standing, or walking, is recommended in many guidelines, 
but, as with most nursing and therapist interventions, 
the evidence base has been weak. The rationale for early 
and more intensive mobilisatio n is that bed rest might 
increase immobility-related complications and could slow 
neurological recovery by impairing early brain plasticity 
and repair. On the other hand, forced sitting and standing 
might lead to falls and injury and could reduce cerebral 
perfusion, autoregulation being impaired in acute stroke, 
and thereby exacerbate ischaemia. Early mobilisation 
might also worsen any post-stroke hypertension 
and increase the risk of rebleeding after intracerebral 
haemorrhage or after thrombolysis for ischaemic stroke.
In The Lancet, the AVERT Collaboration group 
randomly assigned 2104 patients within 24 h of onset 
of acute stroke to early mobilisation or usual care.2 
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strengthened. If recommendations were to support 
use of the vaccine with booster in the 5–17 months age 
range, at least two new visits for immunisation and a 
new visit for the booster would be needed. 
Malaria remains an ongoing public health crisis 
in many settings in sub-Saharan Africa. Every day, 
on average, about 1200 children die in sub-Saharan 
Africa from malaria.5 This ﬁ gure is a substantial 
reduction from mortality estimates 15 years ago, 
and the decline has been associated with scale-up 
in longlasting insecticidal nets, access to eﬀ ective 
artemisinin-combination treat ments, and other WHO 
recommended control measures. Nevertheless, present 
mortality owing to malaria is unacceptable. Drug 
and insecticide resistance are major threats, and new 
malaria interventions are necessary.
The donor community would need to coordinate any 
ﬁ nancing for the RTS,S/AS01 vaccine carefully, should 
it reach that stage. In particular, funding must not 
be redirected away from meeting adequate access to 
artemisinin-combination treatments, rapid diagnostic 
tests, longlasting insecticidal nets, and other malaria 
control measures already in place in some settings, and 
ﬁ nancial resources might be better raised through the 
GAVI Alliance, if their board chooses to support such 
a role. GAVI has a strong track record for ﬁ nancing the 
delivery of new vaccines in sub-Saharan Africa. Finally, 
strong guidance is needed about the role of the vaccine 
in the context of existing malaria control measures, and 
about which malaria transmission intensity settings 
are best suited for vaccine use. The outcomes of 
regulatory and global policy assessments will no doubt 
be of interest to policy makers in malaria-endemic 
countries and multilateral ﬁ nancing agencies. WHO 
has a major responsibility to articulate evidence-based 
policy recommendations for use to support decision 
making in malaria-endemic countries.
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The intervention tested was not simply earlier, but was 
also more frequent and of a higher dose than usual 
care. Indeed, the diﬀ erence achieved in frequency and 
dose was greater than the diﬀ erence in timing of ﬁ rst 
mobilisation (median 18 h vs 22 h after stroke onset). 
The trial was well designed and executed, with only 
six patients lost to follow-up, and external validity 
seems likely to be good. Participating sites were located 
in both metropolitan and regional settings, and ranged 
in size from 33 to 1200 stroke admissions per year. 
Although the trial took 8 years to recruit patients from 
56 acute stroke units, the proportion of eligible patients 
recruited was higher than in many acute stroke trials,3 
and patient refusals (n=446) were remarkably low. The 
3 month mortality rate of only 8% was less than half of 
that reported in previous acute stroke trials,4 perhaps 
because relatively minor strokes were eligible.
The investigators hypothesised that more intensive, 
early out-of-bed activity would improve functional 
outcome at 3 months, reduce immobility-related 
complications, and accelerate walking recovery, with no 
increase in neurological complications. None of these 
predictions proved correct. There was no diﬀ erence in 
walking recovery between the early mobilisation group 
and the usual care group, and a good overall functional 
outcome at 3 months (the primary outcome) was less 
frequent in the intervention group (adjusted odds ratio 
[OR] 0·73, 95% CI 0·59–0·90). The unadjusted result for the 
primary outcome was less convincingly adverse (OR 0·85, 
95% CI 0·72–1·00), but the adjustment for age and stroke 
severity was robust to diﬀ erent analysis methods.
The absence of a diﬀ erence between the groups in 
immobility-related complications might partly be due 
to improvements in stroke-unit practice in the past few 
years and a move away from prolonged bed rest, such 
that only 7% of patients in the usual care group stayed 
in bed for more than 48 h after stroke onset. However, 
the adverse eﬀ ect of the intervention on the primary 
outcome seems to have been driven at least partly by a 
non-signiﬁ cant increase in neurological deterioration in 
the intervention group as compared with the usual care 
group. The non-signiﬁ cant increase in mortality in the 
intervention group was driven mainly by progression 
or recurrence (42 such deaths in the intervention 
group vs 26 deaths in the usual care group). The 
overall increase in mortality in the intervention group 
was non-signiﬁ cant, and remains so when combined 
with the few data (15 deaths in 81 patients with early 
mobilisation vs six deaths in 78 patients with usual 
care) from three small previous trials (ﬁ xed-eﬀ ects 
OR 1·35, 95% CI 0·99–1·83).5 Nevertheless, it seems 
reasonable to conclude that a beneﬁ cial eﬀ ect on 
mortality is unlikely.
In view of the clinical, causal, and physiological 
heterogeneity of acute stroke, subgroup–treatment eﬀ ect 
interactions might well be expected, and many clinicians 
had a-priori concern about starting mobilisation 
early in patients with intracerebral haemorrhage.6 
Therefore, that both the primary outcome (adjusted 
OR 0·48, 95% CI 0·25–0·92) and 3 month mortality 
(0·31, 0·11–0·88) were signiﬁ cantly better in the usual 
care group than the early mobilisation group in patients 
with intracerebral haemorrhage is noteworthy. The 
investigators are cautious in their interpretation of this 
ﬁ nding on the basis that they did not stratify for stroke 
subtype at randomisation and did not prespecify any 
expected subgroup eﬀ ects themselves, and because no 
subgroup–treatment eﬀ ect interaction was statistically 
signiﬁ cant. However, signiﬁ cance is a poor measure of 
the validity of subgroup eﬀ ects,7 partly because most 
trials are substantially underpowered to detect them 
(AVERT recruited only 258 patients with intracerebral 
haemorrhage). Further analyses of frequency and dose of 
intervention received in relation to apparent harms could 
be informative, but updated clinical guidelines should not 
overestimate the statistical obstacles to interpretation of 
what seems to be potentially substantial harm in patients 
with intracerebral haemorrhage, particularly in view of 
the a-priori clinical concern and evidence that excessive 
variability in blood pressure, which might be exacerbated 
by early and intensive mobilisation, is associated with a 
poor outcome in acute intracerebral haemorrhage.8 There 
also seems to be little to lose by a cautious approach to 
early mobilisation in this group.
AVERT is a milestone in stroke research in that it 
has shown that large, international, high-quality 
trials of complex interventions in stroke care, led 
by physiotherapists and nurses, are possible. The 
trial contributes several other important lessons. 
First, it reminds us that high-quality randomised 
controlled trials of acute stroke so often confound 
expectations—the overall balance of beneﬁ ts and 
harms of any intervention are almost impossible to 
predict reliably from ﬁ rst principles. Second, it shows 
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In The Lancet, Mark Barone and colleagues1 report the 
results of their study aimed at establishing whether 
7 day bladder catheterisation is non-inferior to 14 day 
catheterisation in terms of ﬁ stula breakdown after repair, 
in women with simple genital ﬁ stulas. The traditional 
14 day duration of catheterisation after ﬁ stula repair has 
been challenged over the years, although this duration 
has been widely used in practice.2–4 A survey of 40 ﬁ stula 
surgeons by Arrowsmith and colleagues5 reported 
variability of postoperative catheter drainage strategies 
ranging from 5 to 42 days.
Barone and colleagues carried out their randomised, 
controlled, open-label study in hospitals in eight 
African countries. With 261 patients in the 7 day 
group and 263 in the 14 day group in the study, no 
signiﬁ cant diﬀ erence in ﬁ stula repair breakdown, the 
trial’s primary endpoint, was noted between the 7 day 
and 14 day bladder catheterisation groups (ten [4%] of 
250 patients in the 7 day group had repair breakdown 
vs eight [3%] of 251 in the 14 day group, risk diﬀ erence 
0·8% [95% CI –2·8 to 4·5], falling within the predeﬁ ned 
non-inferiority margin of 10%). Additionally, no 
signiﬁ cant diﬀ erences were noted in secondary 
outcomes of repair breakdowns 7 days after catheter 
removal or thereafter; urinary retention 1, 3, or 7 days 
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the eﬀ ect that simple interventions can have on 
outcome in this physiologically complex and unstable 
disorder. Findings from the ongoing HeadPoST trial 
(ClinicalTrials.gov, NCT02162017), comparing the 
eﬀ ectiveness of the lying ﬂ at (0°) head position with 
the sitting up (≥30°) head position in the ﬁ rst 24 h of 
admission to hospital with acute stroke, are likely to be 
similarly important in this regard. Finally, the low rate 
of patients refusing to participate in AVERT shows that 
patients also see the importance of simple, pragmatic 
research questions. Ironically, the main barriers to more 
such research are those put up by agencies intended to 
represent the public interest: the trial regulators with 
their unnecessarily complex bureaucratic framework 
for trial performance, which often results in trial 
prevention, and the medical research funding agencies 
that in many countries have little interest in the needs 
of patients and clinicians for answers to pragmatic 
questions about making the best use of existing 
interventions in routine clinical practice.9 Thankfully, 
those agencies in Australia and the UK that funded 
AVERT took a diﬀ erent view.
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